Zentalis Pharmaceuticals (Zentalis Pharmaceuticals) Debt-to-Equity : 0.09 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals Debt-to-Equity?

Zentalis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Zentalis Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $42.62 Mil. Zentalis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $458.77 Mil. Zentalis Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zentalis Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ZNTL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.05 Max: 0.15
Current: 0.09

During the past 6 years, the highest Debt-to-Equity Ratio of Zentalis Pharmaceuticals was 0.15. The lowest was -0.01. And the median was 0.05.

ZNTL's Debt-to-Equity is ranked better than
61.78% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs ZNTL: 0.09

Zentalis Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Zentalis Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentalis Pharmaceuticals Debt-to-Equity Chart

Zentalis Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.01

0.01

0.13

0.10

Zentalis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.12	0.09	0.10	0.10	0.09

Competitive Comparison of Zentalis Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zentalis Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Debt-to-Equity falls into.

Zentalis Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zentalis Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	43.15)	/	437.284
	=	0.10

Zentalis Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	42.616)	/	458.771
	=	0.09

Zentalis Pharmaceuticals (NAS:ZNTL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zentalis Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zentalis Pharmaceuticals (Zentalis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1359 Broadway, Suite 1710, New York, NY, USA, 10018

Website

https://www.zentalis.com

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Executives

Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein	officer: Chief Medical Officer	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker	officer: Chief Operating Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Melissa B, Epperly	officer: Chief Financial Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman	director	C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Iris Roth	officer: Chief Operating Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Andrea Paul	officer: General Counsel	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Anthony Y Sun	director, officer: President & CEO	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto	officer: Chief Legal Officer	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis	officer: SVP, Clinical Development	C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901